4.5 Article

Nano-formulation of herbo-mineral alternative medicine from linga chenduram and evaluation of antiviral efficacy

Journal

SAUDI JOURNAL OF BIOLOGICAL SCIENCES
Volume 28, Issue 3, Pages 1596-1606

Publisher

ELSEVIER
DOI: 10.1016/j.sjbs.2020.12.005

Keywords

Lingachenduram; Ethnopharmacology; Herbo-mineral nanomedicines; SARS-CoV2; HCV

Categories

Funding

  1. King Saud University, Riyadh, Saudi Arabia [RSP-2020/228]

Ask authors/readers for more resources

Traditional herbomineral formulations in nanoform have shown potential therapeutic effects against viral hepatitis infection, with inhibitory effects on HCV replication and minimal cytotoxicity on human hepatoma cells. These formulations may have promising applications in treating COVID-19 infections.
Traditional medicine is becoming a primary source of health care in many countries in recent years. The current study proposes a new dimension of understanding a traditional origin treatment, using herbomineral preparations in nanoform. The herbo-mineral preparation, Linga chenduram [HMLC], was prepared according to the ancient palm script protocol dates back to 1000 years. In search of alternative therapy for the coronavirus, an attempt was made to determine this ethnic medicine formulation's therapeutic potential for viral hepatitis infection. The Hepatitis C virus [HCV] has several genomic similarities with SARS-CoV-2 viruses. The herbo-mineral formulation (HMLC) were analyzed using UV-vis, EDAX, FTIR, XRD, SEM, and TEM studies. SEM images confirmed the 'presence of nanoparticles with agglomerated conditions having an average grain size of 18 to 25 nm. EDAX studies showed the presence of metallic components in oxide or sulfide form in HMLC. The HCV inhibitory effects of HMLC indicated a good response. The cytotoxicity of this preparation against the Huh-7 human hepatoma cell line was significant. The HMLC showed a strong inhibitory effect on HCV replication in a dose-dependent manner. The genomic component of HCV is similar to COVID -19 virus. The Hepatitis C virus (HCV) NS3/4A protease has a striking three-dimensional structural similarity to the SARS-CoV2 M-pro protease, particularly in the arrangement of key active site residues. So HMLC can be tried to treat coronavirus infection. At higher concentrations, HMLC exhibited over 100-fold inhibition. In the MTT assay, HMLC did not show any apparent cytotoxic effect on cell viability at the concentrations 1-100 mu g. Histological studies indicated that the liver and kidney did not experience any toxicity by 7 and 15 consecutive days of administration of HMLC on experimental Wistar rats. Hence, the HMLC can be tried as a therapy for COVID -19 infections using the preparations strictly according to ethnopharmacological protocol and optimum doses. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available